2026 Q1 -tulosraportti
75 päivää sitten
‧27 min
1,15 DKK/osake
Viimeisin osinko
2,73%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
Vuosittainen yhtiökokous 2026 18.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·2 päivää sittenToday's Stock News 24/07/2026: Lundbeck HLUN B Analyst Comment 24.07.2026, 08.40 Victor SkriverEquity Research Assistant Follow Share Overview Lundbeck has received Fast Track status from the FDA for their oral orexin 2 receptor agonist Lu AH69593 for the treatment of narcolepsy, which accelerates the development and approval process. The news strengthens Lundbeck's strategic shift towards rare neurological diseases and sleep-wake disorders, but the commercial significance remains uncertain due to the early development stage. The orexin program adds depth to Lundbeck's pipeline, while the Phase III candidates bexicaserin and amlenetug are expected to be the nearest catalysts towards patent expiry around 2030. This content is generated by AI. You can provide feedback on it on the Inderes forum. Show less Lundbeck announced yesterday that the US FDA has granted the company's oral orexin 2 receptor agonist Lu AH69593 Fast Track status for the treatment of narcolepsy. The designation accelerates the development and approval process for drugs for serious conditions with unmet needs and constitutes an early regulatory recognition of the candidate, which is currently in Phase 1b. In light of our investment case, the news adds to the broader narrative that the late-stage Phase III candidates bexicaserin and amlenetug provide the nearest catalysts towards patent expirations around 2030, while the orexin program adds depth and optionality further out in the pipeline. The milestone thus supports the company's strategic shift towards rare neurological diseases and sleep-wake disorders, although the early development stage means that the commercial significance remains subject to considerable uncertainty. Read the full news here: https://www.inderes.dk/releases/h-lundbeck-as-lundbeck-receives-fda-fast-track-designation-for-lu-ah69593-an-investigational-orexin-2-receptor-agonist-for-narcolepsy Disclaimer: HC Andersen Capital receives payment from the mentioned companies for a Digital IR subscription agreement. /Victor Skriver on 24/07-2026 at 08:40.
·20.7.yes, good news unfortunately means a stock price drop, but I believe in Lundbeck, a competent company. I'm holding and buying more.
·14.7.Unfortunately, price targets in the mid/late 50s have not proven sustainable. When it reaches around 45, it falls again back towards 40 or lower, as was recently the case. Although the news about product development has generally been positive over the past year.- ·24.6.H. Lundbeck A/S: Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026. Five presentations on migraine will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment bocunebart. The eptinezumab data explore patient-centered outcomes in chronic migraine beyond traditional endpoints, including acute medication use, mental well-being, and workplace productivity. The late-breaker presentation on bocunebart will provide further insight into the inhibition of the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway as a potential new approach to migraine prevention in patients with previous preventive treatment failures. Lundbeck's EAN 2026 program underscores the company's commitment to addressing the broader burden of the disease and continued scientific innovation around existing unmet needs. Valby, Denmark, Wednesday, June 24, 2026 – H. Lundbeck A/S (Lundbeck) announced today that new clinical data on migraine will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place from June 27-30 in Geneva, Switzerland. The presentations will include new analyses of eptinezumab data exploring outcomes that reflect the broader burden of chronic migraine beyond just migraine frequency. Lundbeck will also present Phase IIb PROCEED primary data for bocunebart, an investigational treatment targeting pituitary adenylate cyclase-activating polypeptide (PACAP) under development for migraine prevention. Together, these EAN presentations highlight Lundbeck's dual focus on migraine: optimizing the use of current preventive treatment options while developing future therapeutic approaches for people who continue to experience a significant disease burden. Bocunebart data provide insight into PACAP pathway inhibition in migraine prevention Among the highlights at EAN 2026 are data for bocunebart, a monoclonal antibody (mAb) designed to inhibit PACAP, a neuropeptide involved in migraine pathophysiology, which differs from anti-calcitonin gene-related peptide (aCGRP). PROCEED investigated the efficacy, safety, dosing, and route of administration of bocunebart in adults with migraine where one to four previous preventive treatments had failed. "The presentation advances the growing scientific understanding of PACAP pathway inhibition as a potential new approach to migraine prevention for patients who continue to experience suboptimal disease control despite current preventive treatment options," said Andrew Blumenfeld MD, Cedars Sinai Los Angeles and presenter of the PROCEED results at EAN 2026. Eptinezumab data highlight patient-focused measures of migraine prevention Lundbeck will also present new analyses from the Phase III SUNRISE and Phase IV RESOLUTION studies on eptinezumab, investigating treatment outcomes that reflect the broader clinical, functional, and psychological burden of migraine. Three presentations from the RESOLUTION study will focus on adults living with chronic migraine and medication overuse headache (MOH), a patient group where migraine prevention is complicated by frequent headaches, high acute medication use, and a significant disease burden. The analyses will look at treatment outcomes with eptinezumab across different European countries, patterns of acute medication use over time, and changes in symptoms of anxiety and depression, which often accompany chronic migraine. Additionally, the SUNRISE analysis will investigate the effect of eptinezumab on productivity and activity limitation in the workplace in chronic migraine across regions in Asia and Europe. "The burden of migraine extends far beyond the number of headache days. For many living with migraine, the disease can affect multiple aspects of daily life, but these impacts are not always fully captured in traditional measures of treatment benefit," said Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck. "At EAN 2026, we are presenting data that reflect a broader view of migraine prevention, while also advancing the scientific understanding of PACAP pathway inhibition through our investigational drug bocunebart. Collectively, these presentations reflect Lundbeck's commitment to advancing brain health in areas of unmet need." Details on Lundbeck's presentations at EAN 2026
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
75 päivää sitten
‧27 min
1,15 DKK/osake
Viimeisin osinko
2,73%Tuotto/v
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenToday's Stock News 24/07/2026: Lundbeck HLUN B Analyst Comment 24.07.2026, 08.40 Victor SkriverEquity Research Assistant Follow Share Overview Lundbeck has received Fast Track status from the FDA for their oral orexin 2 receptor agonist Lu AH69593 for the treatment of narcolepsy, which accelerates the development and approval process. The news strengthens Lundbeck's strategic shift towards rare neurological diseases and sleep-wake disorders, but the commercial significance remains uncertain due to the early development stage. The orexin program adds depth to Lundbeck's pipeline, while the Phase III candidates bexicaserin and amlenetug are expected to be the nearest catalysts towards patent expiry around 2030. This content is generated by AI. You can provide feedback on it on the Inderes forum. Show less Lundbeck announced yesterday that the US FDA has granted the company's oral orexin 2 receptor agonist Lu AH69593 Fast Track status for the treatment of narcolepsy. The designation accelerates the development and approval process for drugs for serious conditions with unmet needs and constitutes an early regulatory recognition of the candidate, which is currently in Phase 1b. In light of our investment case, the news adds to the broader narrative that the late-stage Phase III candidates bexicaserin and amlenetug provide the nearest catalysts towards patent expirations around 2030, while the orexin program adds depth and optionality further out in the pipeline. The milestone thus supports the company's strategic shift towards rare neurological diseases and sleep-wake disorders, although the early development stage means that the commercial significance remains subject to considerable uncertainty. Read the full news here: https://www.inderes.dk/releases/h-lundbeck-as-lundbeck-receives-fda-fast-track-designation-for-lu-ah69593-an-investigational-orexin-2-receptor-agonist-for-narcolepsy Disclaimer: HC Andersen Capital receives payment from the mentioned companies for a Digital IR subscription agreement. /Victor Skriver on 24/07-2026 at 08:40.
- ·20.7.yes, good news unfortunately means a stock price drop, but I believe in Lundbeck, a competent company. I'm holding and buying more.
- ·14.7.Unfortunately, price targets in the mid/late 50s have not proven sustainable. When it reaches around 45, it falls again back towards 40 or lower, as was recently the case. Although the news about product development has generally been positive over the past year.
- ·24.6.H. Lundbeck A/S: Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026. Five presentations on migraine will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment bocunebart. The eptinezumab data explore patient-centered outcomes in chronic migraine beyond traditional endpoints, including acute medication use, mental well-being, and workplace productivity. The late-breaker presentation on bocunebart will provide further insight into the inhibition of the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway as a potential new approach to migraine prevention in patients with previous preventive treatment failures. Lundbeck's EAN 2026 program underscores the company's commitment to addressing the broader burden of the disease and continued scientific innovation around existing unmet needs. Valby, Denmark, Wednesday, June 24, 2026 – H. Lundbeck A/S (Lundbeck) announced today that new clinical data on migraine will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place from June 27-30 in Geneva, Switzerland. The presentations will include new analyses of eptinezumab data exploring outcomes that reflect the broader burden of chronic migraine beyond just migraine frequency. Lundbeck will also present Phase IIb PROCEED primary data for bocunebart, an investigational treatment targeting pituitary adenylate cyclase-activating polypeptide (PACAP) under development for migraine prevention. Together, these EAN presentations highlight Lundbeck's dual focus on migraine: optimizing the use of current preventive treatment options while developing future therapeutic approaches for people who continue to experience a significant disease burden. Bocunebart data provide insight into PACAP pathway inhibition in migraine prevention Among the highlights at EAN 2026 are data for bocunebart, a monoclonal antibody (mAb) designed to inhibit PACAP, a neuropeptide involved in migraine pathophysiology, which differs from anti-calcitonin gene-related peptide (aCGRP). PROCEED investigated the efficacy, safety, dosing, and route of administration of bocunebart in adults with migraine where one to four previous preventive treatments had failed. "The presentation advances the growing scientific understanding of PACAP pathway inhibition as a potential new approach to migraine prevention for patients who continue to experience suboptimal disease control despite current preventive treatment options," said Andrew Blumenfeld MD, Cedars Sinai Los Angeles and presenter of the PROCEED results at EAN 2026. Eptinezumab data highlight patient-focused measures of migraine prevention Lundbeck will also present new analyses from the Phase III SUNRISE and Phase IV RESOLUTION studies on eptinezumab, investigating treatment outcomes that reflect the broader clinical, functional, and psychological burden of migraine. Three presentations from the RESOLUTION study will focus on adults living with chronic migraine and medication overuse headache (MOH), a patient group where migraine prevention is complicated by frequent headaches, high acute medication use, and a significant disease burden. The analyses will look at treatment outcomes with eptinezumab across different European countries, patterns of acute medication use over time, and changes in symptoms of anxiety and depression, which often accompany chronic migraine. Additionally, the SUNRISE analysis will investigate the effect of eptinezumab on productivity and activity limitation in the workplace in chronic migraine across regions in Asia and Europe. "The burden of migraine extends far beyond the number of headache days. For many living with migraine, the disease can affect multiple aspects of daily life, but these impacts are not always fully captured in traditional measures of treatment benefit," said Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck. "At EAN 2026, we are presenting data that reflect a broader view of migraine prevention, while also advancing the scientific understanding of PACAP pathway inhibition through our investigational drug bocunebart. Collectively, these presentations reflect Lundbeck's commitment to advancing brain health in areas of unmet need." Details on Lundbeck's presentations at EAN 2026
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
Vuosittainen yhtiökokous 2026 18.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
2026 Q1 -tulosraportti
75 päivää sitten
‧27 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 19.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
Vuosittainen yhtiökokous 2026 18.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
2025 Q3 -tulosraportti 12.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 |
1,15 DKK/osake
Viimeisin osinko
2,73%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·2 päivää sittenToday's Stock News 24/07/2026: Lundbeck HLUN B Analyst Comment 24.07.2026, 08.40 Victor SkriverEquity Research Assistant Follow Share Overview Lundbeck has received Fast Track status from the FDA for their oral orexin 2 receptor agonist Lu AH69593 for the treatment of narcolepsy, which accelerates the development and approval process. The news strengthens Lundbeck's strategic shift towards rare neurological diseases and sleep-wake disorders, but the commercial significance remains uncertain due to the early development stage. The orexin program adds depth to Lundbeck's pipeline, while the Phase III candidates bexicaserin and amlenetug are expected to be the nearest catalysts towards patent expiry around 2030. This content is generated by AI. You can provide feedback on it on the Inderes forum. Show less Lundbeck announced yesterday that the US FDA has granted the company's oral orexin 2 receptor agonist Lu AH69593 Fast Track status for the treatment of narcolepsy. The designation accelerates the development and approval process for drugs for serious conditions with unmet needs and constitutes an early regulatory recognition of the candidate, which is currently in Phase 1b. In light of our investment case, the news adds to the broader narrative that the late-stage Phase III candidates bexicaserin and amlenetug provide the nearest catalysts towards patent expirations around 2030, while the orexin program adds depth and optionality further out in the pipeline. The milestone thus supports the company's strategic shift towards rare neurological diseases and sleep-wake disorders, although the early development stage means that the commercial significance remains subject to considerable uncertainty. Read the full news here: https://www.inderes.dk/releases/h-lundbeck-as-lundbeck-receives-fda-fast-track-designation-for-lu-ah69593-an-investigational-orexin-2-receptor-agonist-for-narcolepsy Disclaimer: HC Andersen Capital receives payment from the mentioned companies for a Digital IR subscription agreement. /Victor Skriver on 24/07-2026 at 08:40.
- ·20.7.yes, good news unfortunately means a stock price drop, but I believe in Lundbeck, a competent company. I'm holding and buying more.
- ·14.7.Unfortunately, price targets in the mid/late 50s have not proven sustainable. When it reaches around 45, it falls again back towards 40 or lower, as was recently the case. Although the news about product development has generally been positive over the past year.
- ·24.6.H. Lundbeck A/S: Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026. Five presentations on migraine will showcase Lundbeck's current and future approaches to migraine prevention, including new data for eptinezumab and Phase IIb PROCEED primary data for the investigational treatment bocunebart. The eptinezumab data explore patient-centered outcomes in chronic migraine beyond traditional endpoints, including acute medication use, mental well-being, and workplace productivity. The late-breaker presentation on bocunebart will provide further insight into the inhibition of the pituitary adenylate cyclase-activating polypeptide (PACAP) pathway as a potential new approach to migraine prevention in patients with previous preventive treatment failures. Lundbeck's EAN 2026 program underscores the company's commitment to addressing the broader burden of the disease and continued scientific innovation around existing unmet needs. Valby, Denmark, Wednesday, June 24, 2026 – H. Lundbeck A/S (Lundbeck) announced today that new clinical data on migraine will be presented at the European Academy of Neurology (EAN) Congress 2026, taking place from June 27-30 in Geneva, Switzerland. The presentations will include new analyses of eptinezumab data exploring outcomes that reflect the broader burden of chronic migraine beyond just migraine frequency. Lundbeck will also present Phase IIb PROCEED primary data for bocunebart, an investigational treatment targeting pituitary adenylate cyclase-activating polypeptide (PACAP) under development for migraine prevention. Together, these EAN presentations highlight Lundbeck's dual focus on migraine: optimizing the use of current preventive treatment options while developing future therapeutic approaches for people who continue to experience a significant disease burden. Bocunebart data provide insight into PACAP pathway inhibition in migraine prevention Among the highlights at EAN 2026 are data for bocunebart, a monoclonal antibody (mAb) designed to inhibit PACAP, a neuropeptide involved in migraine pathophysiology, which differs from anti-calcitonin gene-related peptide (aCGRP). PROCEED investigated the efficacy, safety, dosing, and route of administration of bocunebart in adults with migraine where one to four previous preventive treatments had failed. "The presentation advances the growing scientific understanding of PACAP pathway inhibition as a potential new approach to migraine prevention for patients who continue to experience suboptimal disease control despite current preventive treatment options," said Andrew Blumenfeld MD, Cedars Sinai Los Angeles and presenter of the PROCEED results at EAN 2026. Eptinezumab data highlight patient-focused measures of migraine prevention Lundbeck will also present new analyses from the Phase III SUNRISE and Phase IV RESOLUTION studies on eptinezumab, investigating treatment outcomes that reflect the broader clinical, functional, and psychological burden of migraine. Three presentations from the RESOLUTION study will focus on adults living with chronic migraine and medication overuse headache (MOH), a patient group where migraine prevention is complicated by frequent headaches, high acute medication use, and a significant disease burden. The analyses will look at treatment outcomes with eptinezumab across different European countries, patterns of acute medication use over time, and changes in symptoms of anxiety and depression, which often accompany chronic migraine. Additionally, the SUNRISE analysis will investigate the effect of eptinezumab on productivity and activity limitation in the workplace in chronic migraine across regions in Asia and Europe. "The burden of migraine extends far beyond the number of headache days. For many living with migraine, the disease can affect multiple aspects of daily life, but these impacts are not always fully captured in traditional measures of treatment benefit," said Johan Luthman, Executive Vice President and Head of Research & Development at Lundbeck. "At EAN 2026, we are presenting data that reflect a broader view of migraine prevention, while also advancing the scientific understanding of PACAP pathway inhibition through our investigational drug bocunebart. Collectively, these presentations reflect Lundbeck's commitment to advancing brain health in areas of unmet need." Details on Lundbeck's presentations at EAN 2026
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt